257 related articles for article (PubMed ID: 25285595)
1. Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the explore study.
Freidel M; Ortler S; Fuchs A; Seibert S; Schuh K
J Neurosci Nurs; 2015 Feb; 47(1):E31-9. PubMed ID: 25285595
[TBL] [Abstract][Full Text] [Related]
2. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
3. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Pozzilli C; Schweikert B; Ecari U; Oentrich W; Bugge JP
J Neurol; 2012 Nov; 259(11):2319-28. PubMed ID: 22527232
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
Patti F; Penaherrera JN; Zieger L; Wicklein EM
BMC Neurol; 2021 Aug; 21(1):324. PubMed ID: 34425763
[TBL] [Abstract][Full Text] [Related]
6. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
Keating MM; Ostby PL
J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
[TBL] [Abstract][Full Text] [Related]
7. Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).
Hadjigeorgiou G; Dardiotis E; Tsivgoulis G; Doskas T; Petrou D; Makris N; Vlaikidis N; Thomaidis T; Kyritsis A; Fakas N; Treska X; Karageorgiou C; Sotirli S; Giannoulis C; Papadimitriou D; Mylonas I; Kouremenos E; Vlachos G; Georgiopoulos D; Mademtzoglou D; Vikelis M; Zintzaras E
PLoS One; 2014; 9(11):e113933. PubMed ID: 25419842
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
Limmroth V; Hechenbichler K; Müller C; Schürks M
J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
[TBL] [Abstract][Full Text] [Related]
9. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
10. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
11. Nursing management of MS patients receiving interferon beta-1b therapy.
Costello K; Conway K
Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
13. Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
Zettl UK; Schreiber H; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Hecker M;
Acta Neurol Scand; 2017 Aug; 136(2):116-121. PubMed ID: 27796033
[TBL] [Abstract][Full Text] [Related]
14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
15. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
[TBL] [Abstract][Full Text] [Related]
16. Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study.
Kotterba S; Neusser T; Norenberg C; Bussfeld P; Glaser T; Dörner M; Schürks M
BMC Neurol; 2018 Aug; 18(1):123. PubMed ID: 30143019
[TBL] [Abstract][Full Text] [Related]
17. The multiple sclerosis nurse as patient educator.
Leino-Kilpi H; Luoto E
J Neurosci Nurs; 2001 Apr; 33(2):83-9. PubMed ID: 11326623
[TBL] [Abstract][Full Text] [Related]
18. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
19. Interferon-β-1b: a review of its use in multiple sclerosis.
Plosker GL
CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695
[TBL] [Abstract][Full Text] [Related]
20. A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol.
Jongen PJ; Heerings M; Lemmens WA; Donders R; van der Zande A; van Noort E; Kool A
BMC Neurol; 2015 Aug; 15():128. PubMed ID: 26238866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
